Skip to content

Study · Randomized controlled trial · n = 26 · 2016

5 results

PTH(1-34) for the Primary Prevention of Postthyroidectomy Hypocalcemia: The THYPOS Trial.

Palermo A, Mangiameli G, Tabacco G, Longo F, Pedone C, Briganti SI, Maggi D, Vescini F, Naciu A, Lauria Pantano A, Napoli N, Angeletti S, Pozzilli P, Crucitti P, Manfrini S

The Journal of clinical endocrinology and metabolism15 Aug 2016Cited by 11 (Europe PMC)

PMID27525532 (opens in a new tab)DOI10.1210/jc.2016-2530 (opens in a new tab)PepBankPUB-27525532
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    After thyroidectomy, teriparatide reduced hypocalcemia versus standard care, with 3/13 versus 11/13 cases and relative risk 0.26.

    In plain wordsAfter thyroidectomy, hypocalcemia occurred less often with teriparatide than standard care.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseHypocalcemia incidence and risk
    Study

    n = 26

    Comparator
    Standard clinical care
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    20 mcg every 12 hours · subcutaneous · until dischargeAs given in this study (human).

    Measurements

    Hypocalcemia incidence
    3 of 13 patients
    teriparatide group
    Hypocalcemia incidence
    11 of 13 patients
    control group, standard clinical care
    Relative risk of hypocalcemia
    0.26 ratio
    teriparatide versus control, 95% CI 0.09-0.723

    Source sentences

    Summary
    Overall, the incidence of hypocalcemia was 3/13 in treatment group and 11/13 in the control group (P = .006).
    4 context sentences
    Summary · context
    Treated patients had a lower risk of hypocalcemia than controls (relative risk, 0.26 [95% confidence interval, 0.09-0.723)]).
    Summary · context
    This was a prospective phase II randomized open-label trial.
    Summary · context
    Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
    Summary · context
    Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
  2. 02HumanRandomized controlled trialEfficacy outcome

    After thyroidectomy, median hospitalization was 2 days with teriparatide versus 3 days with standard care.

    In plain wordsAfter thyroidectomy, hospitalization was shorter with teriparatide than standard care.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseHospitalization duration
    Study

    n = 26

    Comparator
    Standard clinical care
    Outcome group
    Intensive care and hospital outcomes · Whole body
    Studied dose
    20 mcg every 12 hours · subcutaneous · until dischargeAs given in this study (human).

    Measurements

    Median hospitalization duration
    3 days
    control group, standard clinical care
    Median hospitalization duration
    2 days
    teriparatide group

    Source sentences

    Summary
    The median duration of hospitalization was 3 days (interquartile range, 1) in control subjects and 2 days (interquartile range, 0) in treated subjects (P = .012).
    3 context sentences
    Summary · context
    This was a prospective phase II randomized open-label trial.
    Summary · context
    Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
    Summary · context
    Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
  3. 03HumanRandomized controlled trialEfficacy outcome

    One month after thyroidectomy discharge, 10/13 teriparatide-treated patients stopped calcium carbonate versus 5/13 controls.

    In plain wordsAfter thyroidectomy, more teriparatide-treated patients stopped calcium supplements than patients with standard care.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseCalcium carbonate cessation
    Study

    n = 26

    Comparator
    Standard clinical care
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    20 mcg every 12 hours · subcutaneous · until dischargeAs given in this study (human).

    Measurements

    Stopped calcium carbonate supplements
    10 of 13 patients
    teriparatide group, 1 month after discharge
    Stopped calcium carbonate supplements
    5 of 13 patients
    control group, 1 month after discharge

    Source sentences

    Summary
    One month after discharge, 10/13 subjects in the treatment group had stopped calcium carbonate supplements, while only 5/13 in the control group had discontinued calcium.
    3 context sentences
    Summary · context
    This was a prospective phase II randomized open-label trial.
    Summary · context
    Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
    Summary · context
    Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
  4. 04HumanRandomized controlled trialEfficacy outcome

    After thyroidectomy, calcium supplementation differed significantly between teriparatide and standard care groups at the one-month visit.

    In plain wordsAfter thyroidectomy, calcium supplementation differed between teriparatide and standard care groups at the one-month visit.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedCalcium supplementation between groups
    Study

    n = 26

    Comparator
    Standard clinical care
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    20 mcg every 12 hours · subcutaneous · until dischargeAs given in this study (human).

    Source sentences

    Summary
    The ANOVA for repeated measures showed a significant difference in calcium supplements between groups at 1-month visit (P = .04)
    3 context sentences
    Summary · context
    This was a prospective phase II randomized open-label trial.
    Summary · context
    Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
    Summary · context
    Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).
  5. 05HumanRandomized controlled trialEfficacy outcome

    After thyroidectomy, calcium supplementation changed significantly between discharge and the one-month visit in the teriparatide group.

    In plain wordsAfter thyroidectomy, calcium supplementation changed between discharge and the one-month visit in the teriparatide group.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    Direction not reportedCalcium supplementation over time
    Study

    n = 13

    Comparator
    Discharge
    Outcome group
    Electrolyte balance · Endocrine and hormones
    Studied dose
    20 mcg every 12 hours · subcutaneous · until dischargeAs given in this study (human).

    Source sentences

    Summary
    as well as a significant difference between discharge and 1-month visit in the treatment group (P for interaction time group = .04)
    3 context sentences
    Summary · context
    This was a prospective phase II randomized open-label trial.
    Summary · context
    Twenty-six subjects (six males, 20 females) with intact PTH lower than10 pg/ml 4 hours after thyroidectomy were included.
    Summary · context
    Subjects were randomized (1:1) to receive SC administration of 20 mcg of teriparatide every 12 hours until the discharge (treatment group) or to follow standard clinical care (control group).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.